CY1112013T1 - Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο - Google Patents
Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικοInfo
- Publication number
- CY1112013T1 CY1112013T1 CY20111101071T CY111101071T CY1112013T1 CY 1112013 T1 CY1112013 T1 CY 1112013T1 CY 20111101071 T CY20111101071 T CY 20111101071T CY 111101071 T CY111101071 T CY 111101071T CY 1112013 T1 CY1112013 T1 CY 1112013T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diabetic
- disease
- renal
- myocardial infarction
- hypertension
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229910052791 calcium Inorganic materials 0.000 title 1
- 239000011575 calcium Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000010125 myocardial infarction Diseases 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 206010003662 Atrial flutter Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 abstract 1
- 206010021263 IgA nephropathy Diseases 0.000 abstract 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000001969 hypertrophic effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- 206010038464 renal hypertension Diseases 0.000 abstract 1
- 239000002461 renin inhibitor Substances 0.000 abstract 1
- 229940086526 renin-inhibitors Drugs 0.000 abstract 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Η εφεύρεση αναφέρεται σε ένα φαρμακευτικό σκεύασμα που περιλαμβάνει (i) έναν αναστολέα ρενίνης, (ii) έναν αναστολέα διαύλων ασβεστίου (CCB), και (iii) ένα διουρητικό και σε μια μέθοδο για τη θεραπευτική αντιμετώπιση μιας κατάστασης ή μιας ασθένειας που επιλέγεται από την ομάδα που περιλαμβάνει την υπέρταση, τη καρδιακή ανεπάρκεια όπως είναι η (οξεία και χρόνια) συμφορητική καρδιακή ανεπάρκεια, τη δυσλειτουργία της αριστερής κοιλίας και την υπερτροφική μυοκαρδιοπάθεια, τη διαβητική μυοκαρδιοπάθεια, τις υπερκοιλιακές και κοιλιακές αρρυθμίες, τη κολπική μαρμαρυγή, τον κολπικό πτερυγισμό, τη καταστροφική αναδιαμόρφωση των αγγείων, το έμφραγμα του μυοκαρδίου και τις συνέπειες αυτού, την αθηροσκλήρυνση, τη στηθάγχη (ασταθή ή σταθερή), τη νεφρική ανεπάρκεια (διαβητική και μη-διαβητική), τη καρδιακή ανεπάρκεια, τη στηθάγχη, το διαβήτη, το δευτεροπαθή αλδοστερινισμό, τη πρωτοπαθή και δευτεροπαθή πνευμονική υπέρταση, τις καταστάσεις νεφρικής ανεπάρκειας, όπως είναι η διαβητική νεφροπάθεια, η σπειραματονεφρίτιδα (περιλαμβανομένης της IgA νεφροπάθειας), η νεφρική ίνωση, το σκληρόδερμα, η σπειραματοσκλήρυνση, η πρωτεϊνουρία της νεφρικής νόσου, καθώς επίσης και η νεφραγγειακή υπέρταση, τη διαβητική αμφιβληστροειδοπάθεια, την αντιμετώπιση άλλων αγγειακών διαταραχών, όπως είναι η ημικρανία, η περιφερική αγγειακή νόσος, η νόσος του Raynaud, η ενδοαυλική υπερπλασία, η γνωσιακή δυσλειτουργία (όπως είναι η νόσος Alzheimer), το γλαύκωμα και το αγγειακό εγκεφαλικό, η πνευμονική και ηπατική ίνωση, ινωτικές ασθένειες που προκύπτουν από τη συσσώρευση περίσσειας εξωκυττάριου στρώματος προκαλούμενη από τον TGF, και νεοπλασματικά νοσήματα των λείων μυϊκών κυττάρων, περιλαμβανομένης της
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38154602P | 2002-05-17 | 2002-05-17 | |
| EP03730064A EP1507558B8 (en) | 2002-05-17 | 2003-05-16 | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112013T1 true CY1112013T1 (el) | 2015-11-04 |
Family
ID=29550141
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111101071T CY1112013T1 (el) | 2002-05-17 | 2011-11-07 | Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο |
| CY2012011C CY2012011I2 (el) | 2002-05-17 | 2012-05-14 | Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2012011C CY2012011I2 (el) | 2002-05-17 | 2012-05-14 | Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20050182042A1 (el) |
| EP (2) | EP2316488A1 (el) |
| JP (2) | JP5288678B2 (el) |
| KR (3) | KR20130109244A (el) |
| CN (1) | CN1655819A (el) |
| AT (1) | ATE520417T1 (el) |
| AU (1) | AU2003240669B2 (el) |
| BR (1) | BR0310084A (el) |
| CA (1) | CA2485081C (el) |
| CY (2) | CY1112013T1 (el) |
| DK (1) | DK1507558T3 (el) |
| EC (1) | ECSP045428A (el) |
| ES (1) | ES2369216T3 (el) |
| HK (1) | HK1074774A1 (el) |
| IL (1) | IL164837A (el) |
| LU (1) | LU92000I2 (el) |
| MX (1) | MXPA04011383A (el) |
| NO (1) | NO334382B1 (el) |
| NZ (1) | NZ536555A (el) |
| PL (1) | PL219032B1 (el) |
| PT (1) | PT1507558E (el) |
| RU (1) | RU2316318C2 (el) |
| SI (1) | SI1507558T1 (el) |
| WO (1) | WO2003097098A1 (el) |
| ZA (1) | ZA200408442B (el) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| CN1655819A (zh) * | 2002-05-17 | 2005-08-17 | 诺瓦提斯公司 | 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物 |
| US7732467B2 (en) | 2003-05-15 | 2010-06-08 | Alzheimer's Institute Of America, Inc. | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| WO2005077418A1 (en) * | 2004-02-17 | 2005-08-25 | Novartis Ag | Combination of renin inhibitor and diuretics |
| BRPI0508880A (pt) * | 2004-03-17 | 2007-09-04 | Novartis Ag | uso de compostos orgánicos |
| MY148773A (en) * | 2004-03-17 | 2013-05-31 | Novartis Ag | Galenic formulations of organic compounds |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| KR20080005926A (ko) * | 2005-03-22 | 2008-01-15 | 노파르티스 아게 | 항고혈압제로서 알리스키렌의 효능에 대한 바이오마커 |
| AU2006311723A1 (en) * | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
| KR20090083918A (ko) * | 2006-11-07 | 2009-08-04 | 노파르티스 아게 | 알리스키렌 헤미푸마레이트의 결정질 형태 |
| KR20090081010A (ko) * | 2006-11-09 | 2009-07-27 | 노파르티스 아게 | 알리스키렌의 오로트산과의 염 |
| ES2409756T3 (es) * | 2006-12-04 | 2013-06-27 | Promedior, Inc. | Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos |
| US20100292335A1 (en) * | 2007-02-16 | 2010-11-18 | Campbell Duncan J | Use of organic compounds |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| US9884899B2 (en) * | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| US8497243B2 (en) * | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| US8236346B2 (en) | 2007-10-05 | 2012-08-07 | Alzheimer's Institute of America, Inc | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
| EP2062874B1 (en) | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| EP2189442B1 (en) | 2008-11-20 | 2014-10-01 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process and intermediates for the preparation of aliskiren |
| JP5980508B2 (ja) * | 2009-03-11 | 2016-08-31 | プロメディオール， インコーポレイテッド | 自己免疫障害に対する処置方法 |
| PT2405928T (pt) * | 2009-03-11 | 2017-02-07 | Promedior Inc | Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| ES2552793T3 (es) * | 2009-06-17 | 2015-12-02 | Promedior Inc. | Variantes de SAP y su uso |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| CN102247344A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血压组合物 |
| CN102552277A (zh) * | 2011-12-02 | 2012-07-11 | 邬林祥 | 氨氯地平、阿利可仑和氢氯噻嗪复方降压药物 |
| CN102626391B (zh) * | 2012-04-19 | 2013-07-10 | 海南美兰史克制药有限公司 | 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂 |
| GB201317373D0 (en) | 2013-10-01 | 2013-11-13 | Univ Dundee | Treatment and prevention of cancer |
| CN111789843A (zh) * | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
| KR102414285B1 (ko) * | 2020-06-02 | 2022-06-28 | 이화여자대학교 산학협력단 | 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| EP0565634B1 (en) * | 1990-12-14 | 1999-03-17 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
| US5114925A (en) * | 1991-01-22 | 1992-05-19 | Merck & Co., Inc. | Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives |
| US5256667A (en) * | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| US5202322A (en) * | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
| MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| CA2430924A1 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition |
| DE60227679D1 (de) * | 2001-09-11 | 2008-08-28 | Asahi Kasei Pharma Corp | Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen |
| US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| CN1655819A (zh) * | 2002-05-17 | 2005-08-17 | 诺瓦提斯公司 | 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物 |
-
2003
- 2003-05-16 CN CNA03811237XA patent/CN1655819A/zh active Pending
- 2003-05-16 SI SI200332071T patent/SI1507558T1/sl unknown
- 2003-05-16 DK DK03730064.7T patent/DK1507558T3/da active
- 2003-05-16 MX MXPA04011383A patent/MXPA04011383A/es active IP Right Grant
- 2003-05-16 JP JP2004505094A patent/JP5288678B2/ja not_active Expired - Fee Related
- 2003-05-16 RU RU2004137104/15A patent/RU2316318C2/ru not_active IP Right Cessation
- 2003-05-16 EP EP10177741A patent/EP2316488A1/en not_active Withdrawn
- 2003-05-16 ES ES03730064T patent/ES2369216T3/es not_active Expired - Lifetime
- 2003-05-16 US US10/514,683 patent/US20050182042A1/en not_active Abandoned
- 2003-05-16 AU AU2003240669A patent/AU2003240669B2/en not_active Ceased
- 2003-05-16 AT AT03730064T patent/ATE520417T1/de active
- 2003-05-16 KR KR1020137023159A patent/KR20130109244A/ko not_active Application Discontinuation
- 2003-05-16 WO PCT/EP2003/005188 patent/WO2003097098A1/en active IP Right Grant
- 2003-05-16 PL PL372203A patent/PL219032B1/pl unknown
- 2003-05-16 KR KR1020107028689A patent/KR20100137026A/ko active Application Filing
- 2003-05-16 EP EP03730064A patent/EP1507558B8/en not_active Expired - Lifetime
- 2003-05-16 CA CA2485081A patent/CA2485081C/en not_active Expired - Fee Related
- 2003-05-16 KR KR10-2004-7018479A patent/KR20050008717A/ko not_active Application Discontinuation
- 2003-05-16 BR BR0310084-7A patent/BR0310084A/pt not_active Application Discontinuation
- 2003-05-16 NZ NZ536555A patent/NZ536555A/en not_active IP Right Cessation
- 2003-05-16 PT PT03730064T patent/PT1507558E/pt unknown
-
2004
- 2004-10-19 ZA ZA200408442A patent/ZA200408442B/en unknown
- 2004-10-25 IL IL164837A patent/IL164837A/en not_active IP Right Cessation
- 2004-11-12 EC EC2004005428A patent/ECSP045428A/es unknown
- 2004-12-15 NO NO20045459A patent/NO334382B1/no not_active IP Right Cessation
-
2005
- 2005-08-12 HK HK05106985.9A patent/HK1074774A1/xx not_active IP Right Cessation
-
2008
- 2008-08-08 US US12/188,604 patent/US8183295B2/en not_active Expired - Fee Related
-
2010
- 2010-08-13 JP JP2010181380A patent/JP2010280708A/ja not_active Withdrawn
-
2011
- 2011-11-07 CY CY20111101071T patent/CY1112013T1/el unknown
- 2011-11-30 US US13/307,567 patent/US20120071470A1/en not_active Abandoned
-
2012
- 2012-05-14 LU LU92000C patent/LU92000I2/fr unknown
- 2012-05-14 CY CY2012011C patent/CY2012011I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112013T1 (el) | Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο | |
| NO2016009I2 (no) | Sakubitril/valsartan, inkludert farmasøytisk akseptable salter derav | |
| CY1107779T1 (el) | Αντιυπερτασικος συνδυασμος βαλσαρτανης και παρεμποδιστη διαυλου ασβεστιου | |
| WO2007106708A3 (en) | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |